Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Terminated 1Completed 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Plasma cell 2

Conditions

Neoplasms 3Neoplasm Metastasis 3Melanoma 3Glioblastoma 3Central Nervous System Neoplasms 3Carcinoma, Non-Small-Cell Lung 3Breast Neoplasms 3Somatostatinoma 2Sarcoma 2Rectal Neoplasms 2Prostatic Neoplasms 2Neoplasms, Plasma Cell 2Multiple Myeloma 2Mesothelioma, Malignant 2Insulinoma 2Glucagonoma 2Gliosarcoma 2Gastrinoma 2Colorectal Neoplasms 2Colonic Neoplasms 2Carcinoma, Renal Cell 2Carcinoma, Islet Cell 2Brain Neoplasms 2von Hippel-Lindau Disease 1Vipoma 1Uterine Cervical Neoplasms 1Unspecified Adult Solid Tumor, Protocol Specific 1Solitary Fibrous Tumor, Pleural 1Primary Myelofibrosis 1Pheochromocytoma 1

Interventions

Dexamethasone 110Cyclophosphamide 99Melphalan 91Bortezomib 68Peripheral Blood Stem Cell Transplantation 63Lenalidomide 57fludarabine phosphate 55Busulfan 53Filgrastim 50Antilymphocyte Serum 38Tacrolimus 37Thalidomide 36Radiotherapy 36Mycophenolic Acid 32fludarabine 28Cyclosporine 26Methotrexate 25Etoposide 22Calcium Dobesilate 22Prednisone 21Whole-Body Irradiation 20Methylprednisolone 20sargramostim 19pomalidomide 19Granulocyte Colony-Stimulating Factor 18carfilzomib 16daratumumab 15Cord Blood Stem Cell Transplantation 14Carmustine 14Rituximab 13

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Interventional × Neoplasms, Plasma Cell × vatalanib × Clear all
NCT00240162 2014-09-17

PTK/ZK as Post Transplant Maintenance Therapy in Patients With Multiple Myeloma

Washington University School of Medicine

Phase 2 Terminated
21 enrolled 11 charts
Plasma cell

Multiple Myeloma, Neoplasms, Plasma Cell

NCT00165347 2007-12-21

Protein Tyrosine Kinases (PTK) in Multiple Myeloma

Dana-Farber Cancer Institute

Phase 2 Completed
10 enrolled
Plasma cell

Multiple Myeloma, Neoplasms, Plasma Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡